FHL2 and skin basal cell carcinoma: Upon treatment of MSC and/or HEK-293, DAOY, and BCC cells stably expressing empty vector, wild-type FHL2, wild-type GLI2, tGLI2, or the FHL2-GLI2 fusion protein with Vismodegib (Fig. 6a–c) and cyclopamine (Supplementary Fig. 9a–c), both highly specific inhibitors of SMO37, we observed a significant effect on proliferation and colony formation in cells expressing tGLI2 and the FHL2-GLI2 fusion protein (Fig. 6a, b, Supplementary Fig. 9a, b).